 correlation response survival patients multiple myeloma vincristine melphalan cyclophosphamide prednisone vincristine melphalan cyclophosphamide prednisone VMCP multi-drug regimen untreated patients multiple myeloma MM symptomatic Durie Stages II III refractory prognostic significance various pretreatment characteristics terms therapeutic response Southwest Oncology Group SWOG Chronic Leukemia-Myeloma Task Force TF criteria survival Therapeutic responses SWOG TF patients significant inverse correlation myeloma cell mass serum calcium bone status Median survival time Stage II Stage III patients months Serum microglobulin equal micrograms/ml variable survival duration multi-variate analysis risk therapeutic response time-dependent variable effect survival data correlation response survival inadequate response assessment criteria treatment curative current therapeutic approaches death complications